Microgenics keeps technology in management buy-out
This article was originally published in Clinica
Microgenics is buying itself out of Roche Boehringer Mannheim, taking with it the intellectual property rights to the technology it developed before the company was sold, first to Boehringer, and subsequently, in the Boehringer deal, to Roche.
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.